175 related articles for article (PubMed ID: 22727345)
1. Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.
Upson K; Allison KH; Reed SD; Jordan CD; Newton KM; Swisher EM; Doherty JA; Garcia RL
Am J Obstet Gynecol; 2012 Jul; 207(1):36.e1-8. PubMed ID: 22727345
[TBL] [Abstract][Full Text] [Related]
2. The study design and compliance may affect strength of inferences.
Gallos ID; Gupta JK
Am J Obstet Gynecol; 2012 Dec; 207(6):e9-e10; author reply e10. PubMed ID: 22901980
[No Abstract] [Full Text] [Related]
3. Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia.
Amezcua CA; Zheng W; Muderspach LI; Felix JC
Gynecol Oncol; 1999 Apr; 73(1):126-36. PubMed ID: 10094893
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
Sletten ET; Arnes M; Lysa LM; Moe BT; Straume B; Orbo A
Anticancer Res; 2017 May; 37(5):2529-2536. PubMed ID: 28476823
[TBL] [Abstract][Full Text] [Related]
5. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
[TBL] [Abstract][Full Text] [Related]
6. Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia.
Ørbo A; Arnes M; Lyså LM; Straume B
Anticancer Res; 2015 Dec; 35(12):6401-9. PubMed ID: 26637849
[TBL] [Abstract][Full Text] [Related]
7. Progestin therapy of complex endometrial hyperplasia with and without atypia.
Reed SD; Voigt LF; Newton KM; Garcia RH; Allison HK; Epplein M; Jordan D; Swisher E; Weiss NS
Obstet Gynecol; 2009 Mar; 113(3):655-662. PubMed ID: 19300331
[TBL] [Abstract][Full Text] [Related]
8. Specific Biomarker Expression Patterns in the Diagnosis of Residual and Recurrent Endometrial Precancers After Progestin Treatment: A Longitudinal Study.
Chen H; Lucas E; Strickland AL; Carrick K; Gwin K; Castrillon DH; Rivera-Colon G; Niu S; Molberg KH; Zheng W
Am J Surg Pathol; 2020 Oct; 44(10):1429-1439. PubMed ID: 32931681
[TBL] [Abstract][Full Text] [Related]
9. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
[TBL] [Abstract][Full Text] [Related]
10. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
11. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Wheeler DT; Bristow RE; Kurman RJ
Am J Surg Pathol; 2007 Jul; 31(7):988-98. PubMed ID: 17592264
[TBL] [Abstract][Full Text] [Related]
12. Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system.
Orbo A; Arnes M; Pettersen I; Larsen K; Hanssen K; Moe B
Acta Obstet Gynecol Scand; 2010 Nov; 89(11):1438-46. PubMed ID: 20955098
[TBL] [Abstract][Full Text] [Related]
13. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium.
Minaguchi T; Nakagawa S; Takazawa Y; Nei T; Horie K; Fujiwara T; Osuga Y; Yasugi T; Kugu K; Yano T; Yoshikawa H; Taketani Y
Cancer Lett; 2007 Apr; 248(1):112-22. PubMed ID: 16919866
[TBL] [Abstract][Full Text] [Related]
14. Significance of progesterone receptors (PR-A and PR-B) expression as predictors for relapse after successful therapy of endometrial hyperplasia: a retrospective cohort study.
Sletten ET; Arnes M; Lyså LM; Larsen M; Ørbo A
BJOG; 2019 Jun; 126(7):936-943. PubMed ID: 30548528
[TBL] [Abstract][Full Text] [Related]
15. Analysis of PTEN, estrogen receptor α and progesterone receptor expression in endometrial hyperplasia using tissue microarray.
Pieczyńska B; Wojtylak S; Zawrocki A; Biernat W
Pol J Pathol; 2011 Sep; 62(3):133-8. PubMed ID: 22102068
[TBL] [Abstract][Full Text] [Related]
16. Endometrial squamous metaplasia. An unusual response to progestin therapy of hyperplasia.
Miranda MC; Mazur MT
Arch Pathol Lab Med; 1995 May; 119(5):458-60. PubMed ID: 7748076
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
Amezcua CA; Lu JJ; Felix JC; Stanczyk FZ; Zheng W
Gynecol Oncol; 2000 Nov; 79(2):169-76. PubMed ID: 11063639
[TBL] [Abstract][Full Text] [Related]
18. Involution of PTEN-null endometrial glands with progestin therapy.
Zheng W; Baker HE; Mutter GL
Gynecol Oncol; 2004 Mar; 92(3):1008-13. PubMed ID: 14984979
[TBL] [Abstract][Full Text] [Related]
19. Assessing the prognostic value of PAX2 and PTEN in endometrial carcinogenesis.
Rewcastle E; Varhaugvik AE; Gudlaugsson E; Steinbakk A; Skaland I; van Diermen B; Baak JP; Janssen EAM
Endocr Relat Cancer; 2018 Dec; 25(12):981-991. PubMed ID: 30400021
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
